These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35381779)

  • 1. Modified neoadjuvant clinicopathological risk stratification as a prognostic score in early and locally advanced triple-negative breast cancer.
    Dubashi B; Matta K; Kayal S; Thumathy DB; Nisha Y; Dharanipragada K; Gunaseelan K; Ch Toi P; Ganesan P
    J Cancer Res Ther; 2022; 18(1):168-172. PubMed ID: 35381779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy.
    Marmé F; Solbach C; Michel L; Schneeweiss A; Blohmer JU; Huober J; Fasching PA; Jackisch C; Nekljudova V; Link T; Rhiem K; Rey J; Denkert C; Hanusch C; Tesch H; Lederer B; Loibl S; Untch M
    Eur J Cancer; 2021 Aug; 153():203-212. PubMed ID: 34186505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the efficacy of taxanes with carboplatin and anthracyclines with taxanes in neoadjuvant chemotherapy for stage II-III triple negative breast cancer: a retrospective analysis.
    Wang H; Zhang N; Sun Q; Zhao Z; Pang H; Huang X; Zhang R; Kang W; Shan M
    J Cancer Res Clin Oncol; 2024 Jun; 150(6):291. PubMed ID: 38836955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial.
    Kolberg-Liedtke C; Feuerhake F; Garke M; Christgen M; Kates R; Grischke EM; Forstbauer H; Braun M; Warm M; Hackmann J; Uleer C; Aktas B; Schumacher C; Kuemmel S; Wuerstlein R; Graeser M; Nitz U; Kreipe H; Gluz O; Harbeck N
    Breast Cancer Res; 2022 Sep; 24(1):58. PubMed ID: 36056374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The influence of various myelosuppression degrees during neoadjuvant chemotherapy on the curative effect and prognosis of triple-negative breast cancer].
    Niu YD; Zhang YW; Zhu RJ; Chu T; Wang L; Wang S; Li YY; Dong Y
    Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(29):2290-2294. PubMed ID: 35927061
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of Neoadjuvant
    Philipovskiy A; Corral J; Dwivedi KA; Heydarian R; Gaur S
    In Vivo; 2019; 33(4):1227-1234. PubMed ID: 31280213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unfavorable pathological complete response rate of neoadjuvant chemotherapy epirubicin plus taxanes for locally advanced triple-negative breast cancer.
    Yin Y; Zhang P; Xu BH; Zhang BL; Li Q; Yuan P; Cai RG; Wang JY; Wang X; Xu XZ
    J Huazhong Univ Sci Technolog Med Sci; 2013 Apr; 33(2):262-265. PubMed ID: 23592141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological features of early failure of neoadjuvant chemotherapy in locally advanced breast cancer.
    Choi MK; Park YH; Kil WH; Lee JE; Nam SJ; Ahn JS; Im YH
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):521-9. PubMed ID: 25047725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of intra-arterial neoadjuvant chemotherapy through the superior epigastric artery in the treatment of locally advanced triple negative breast cancer.
    Jin HY; He W; Liu Q; Wang XF; Liu YF; Wei ZX
    Neoplasma; 2016; 63(4):607-16. PubMed ID: 27268925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting.
    Gamucci T; Pizzuti L; Sperduti I; Mentuccia L; Vaccaro A; Moscetti L; Marchetti P; Carbognin L; Michelotti A; Iezzi L; Cassano A; Grassadonia A; Astone A; Botticelli A; Magnolfi E; Di Lauro L; Sergi D; Fuso P; Tinari N; Barba M; Maugeri-Saccà M; Landucci E; Conti F; Sanguineti G; De Tursi M; Iafrate G; Giordano A; Ciliberto G; Natoli C; Vici P
    J Cell Physiol; 2018 Mar; 233(3):2313-2323. PubMed ID: 28710865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response.
    Loibl S; Schneeweiss A; Huober J; Braun M; Rey J; Blohmer JU; Furlanetto J; Zahm DM; Hanusch C; Thomalla J; Jackisch C; Staib P; Link T; Rhiem K; Solbach C; Fasching PA; Nekljudova V; Denkert C; Untch M;
    Ann Oncol; 2022 Nov; 33(11):1149-1158. PubMed ID: 35961599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overall Survival Following Neoadjuvant Chemotherapy Versus Adjuvant Chemotherapy in Clinically Node Negative T1 Triple Negative Breast Cancer.
    Huang K; Jakub J; Gabriel E; Moreno-Aspitia A; McLaughlin S
    Ann Surg Oncol; 2023 Nov; 30(12):7026-7035. PubMed ID: 37490162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy.
    Shi Z; Liu Y; Fang X; Liu X; Meng J; Zhang J
    Sci Rep; 2024 Jul; 14(1):16899. PubMed ID: 39043756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1/2-mutated triple-negative breast cancer.
    Zhang J; Yao L; Liu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Int J Cancer; 2021 Feb; 148(4):941-949. PubMed ID: 32720318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
    Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
    Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival outcomes of neoadjuvant versus adjuvant chemotherapy in triple-negative breast cancer: a meta-analysis of 36,480 cases.
    Xia LY; Hu QL; Zhang J; Xu WY; Li XS
    World J Surg Oncol; 2020 Jun; 18(1):129. PubMed ID: 32539858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome for triple negative breast cancer in a retrospective cohort with an emphasis on response to platinum-based neoadjuvant therapy.
    Walsh EM; Shalaby A; O'Loughlin M; Keane N; Webber MJ; Kerin MJ; Keane MM; Glynn SA; Callagy GM
    Breast Cancer Res Treat; 2019 Feb; 174(1):1-13. PubMed ID: 30488345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. qRT-PCR-based DNA homologous recombination-associated 4-gene score predicts pathologic complete response to platinum-based neoadjuvant chemotherapy in triple-negative breast cancer.
    Zuo K; Yuan X; Liang X; Sun X; Liu S; Connell PP; Li X; Yang W
    Breast Cancer Res Treat; 2022 Jan; 191(2):335-344. PubMed ID: 34797456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world assessment of the effect of impact of tumor size on pathological complete response rates in triple negative breast cancer after neoadjuvant chemotherapy.
    de Paula BHR; Kumar S; Morosini FM; Calábria Cardoso DEM; de Sousa CAM; Crocamo S
    Chin Clin Oncol; 2020 Dec; 9(6):78. PubMed ID: 33183012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
    Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.